Singapore: New fee structure aims to foster innovation

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Singapore: New fee structure aims to foster innovation

The Intellectual Property Office of Singapore (IPOS) announced a fee revision for patents and trade marks with effect from April 1 2017. Regarding patents, the application fees for searches or supplementary search reports, local search and examination reports, and international search and examination reports, are reduced by 14%, 25% and 37%, respectively. There is also a 30% fee reduction in the application to register trade marks that utilise the IPOS pre-approved list of goods and services. Thus, businesses and entrepreneurs will see a substantial fee reduction for patent and trade mark applications.

In addition, a new excess claim fee structure is introduced that is payable when requesting combined search and examination (S&E), examination (E) and grant. Previously, excess claim fees were only payable at time of grant. With the revised fees, $40 is charged per claim in excess of 20 claims when requesting S&E or E and is payable together with a grant fee for claims in excess of the number of claims previously paid (i.e. only the excess unpaid claims will be charged on grant). The changes to the claim fee structure will streamline the patent application process at IPOS and encourage applicants to file claims sets that are concise with the aim of saving costs and time required for the patent application process.

The fee revision also includes an increase in patent renewal fees from the eighth year onwards and an increase in trade mark renewal fees. While this renewal fee revision increases the overall lifecycle costs for patents and trade marks in Singapore, Singapore continues to remain competitive with lower overall lifecycle costs as compared to other countries such as Korea, Japan, China, the USA and Australia.

According to IPOS, the increase in renewal fees will discourage IP hoarding by encouraging IP owners to utilise their valuable IP while releasing non-performing IP to the public domain. To further facilitate this initiative, the fees for surrendering or cancelling IP are removed. Additionally, applicants who license their patents will enjoy a 50% discount off their renewal fees. Thus businesses are encouraged to manage their IP portfolio strategically.

Collopy_Dan

Shahera Anwar

Daniel Collopy


Spruson & Ferguson (Asia) Pte Ltd152 Beach Road#37-05/06 Gateway EastSingapore 189721Tel: +65 6333 7200Fax: +65 6333 7222mail.asia@spruson.comwww.spruson.com

more from across site and SHARED ros bottom lb

More from across our site

The firm said adding capability in the French capital completes its coverage of all major patent litigation jurisdictions as it strives for UPC excellence
Marc Fenster explains how keeping the jury focused on the most relevant facts helped secure a $279m win for his client against Samsung
Clients are divided on what externally funded IP firms bring to the table, so those firms must prove why the benefits outweigh the downsides
Rahul Bhartiya, AI coordinator at the EUIPO, discusses the office’s strategy, collaboration with other IP offices, and getting rid of routine tasks
A boom in transactional work and a heightened awareness of IP have helped boost revenue for the rebranded commercial services team
Clemens Heusch, head of global litigation and dispute resolution at Nokia, tells us why open conversations – and respectful challenges – lead to the best results
Siegmund Gutman, who joined Mintz one year ago, explains the firm’s approach to life sciences litigation and what it means for hiring plans
The merger of two IP boutiques could prompt others to follow suit and challenge Australia’s externally funded firms
Law firm leaders say they are eager to make the most out of the market following a 'surprising' survey on in-house interest in IP monetisation
A defeat for AstraZeneca and Open Innovation Network's 20th anniversary were also among the top talking points this week
Gift this article